NVO — NOVO NORDISK A S
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 353278 ·
Last close
$40.70
Market Cap
$136.10B
52W High
$61.11
52W Low
$34.15
ADV30
11,672,867
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 79,195,000,000 | 60,958,000,000 | 23,011,000,000 | 16,740,000,000 | 599,160,000,000 | 44,151,000,000 | 381,358,000,000 |
| Jun 2026 | 78,488,000,000 | 61,388,000,000 | 27,061,000,000 | 20,989,000,000 | 594,941,000,000 | 44,482,000,000 | 373,664,000,000 |
| Mar 2026 | 96,823,000,000 | 83,225,000,000 | 59,618,000,000 | 48,557,000,000 | 559,221,000,000 | 21,127,000,000 | 356,156,000,000 |
| Dec 2025 | 79,144,000,000 | 63,996,000,000 | 31,736,000,000 | 26,891,000,000 | 542,902,000,000 | 26,464,000,000 | 348,855,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$127,325,000,000
Investing CF
$-83,350,000,000
Financing CF
$-31,871,000,000
CapEx
$-82,356,000,000
Dividends Paid
$-51,896,000,000
Buybacks
$-10,002,000,000
EPS Diluted TTM
$25.48
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$220,552,000,000
Inventory
$51,205,000,000
Receivables
$110,606,000,000
ST Investments
$2,201,000,000
EBIT TTM
$148,793,000,000
Pretax Income TTM
$144,666,000,000
Interest Exp TTM
$2,170,000,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$329,430,990,848
EBITDA
$173,677,002,752
Free Cash Flow
$37,673,250,816
Enterprise Value
$285,861,511,168
Total Cash
$44,982,001,664
Total Debt
$140,126,994,432
Shares Out
3,344,053,124
Trailing EPS
$4.09
Book Value
$7.74
ROE
59.8%
ROA
18.7%
Div Yield
4.17%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 309,064,000,000 | 127,658,000,000 | 102,434,000,000 | 542,902,000,000 | 348,855,000,000 | 194,047,000,000 | 119,102,000,000 |
| Dec 2024 | 290,403,000,000 | 128,339,000,000 | 100,988,000,000 | 465,630,000,000 | 322,144,000,000 | 143,486,000,000 | 120,968,000,000 |
| Dec 2023 | 232,261,000,000 | 102,574,000,000 | 83,683,000,000 | 314,486,000,000 | 207,925,000,000 | 106,561,000,000 | 108,908,000,000 |
| Dec 2022 | 176,954,000,000 | 74,809,000,000 | 55,525,000,000 | 241,257,000,000 | 157,771,000,000 | 83,486,000,000 | 78,887,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $135.44B | $534.20 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $125.40B | $61.35 | — |
| PFE | PFIZER INC | $162.27B | $28.47 | — |
| SNY | Sanofi | $113.89B | $47.53 | — |
| ABT | ABBOTT LABORATORIES | $181.35B | $104.71 | — |
News headlines (Yahoo Finance, 1h cache)
nference and Novo partner to advance understanding of cardiometabolic disease and healthy ageing
2026-11-18 10:30 · Yahoo
Novo Nordisk (NVO) Stock May Be Undervalued On Raised 2026 Outlook
2026-11-18 06:17 · Yahoo
Novo Nordisk (NVO) Could Be 47% Below Fair Value Following Its AI Push
2026-11-18 05:12 · Yahoo
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
2026-11-17 21:37 · Yahoo
European Equities Traded in the US as American Depositary Receipts Tumble in Tuesday Trading
2026-11-17 16:20 · Yahoo
Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
2026-11-17 13:00 · Yahoo
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
2026-11-17 11:45 · Yahoo
Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®
2026-11-16 22:00 · Yahoo
European Stocks Close Mostly Lower in Monday Trading; Investors Parse Earnings, Look Ahead to Trilateral Summit
2026-11-16 16:56 · Yahoo
Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival
2026-11-16 16:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.